A retrospective study found that patients with preexisting autoimmune diseases (PADs) may experience exacerbations during immune checkpoint inhibitor (ICI) treatment, even with background immunosuppression, although these exacerbations tend to be mild.

The study evaluated 27 patients with PAD who were referred for rheumatologic evaluation either before initiating or during immunotherapy treatment between January 2013 and July 2019.

The most prevalent PADs were rheumatoid arthritis (RA, 30%), psoriasis/psoriatic arthritis (30%), inflammatory bowel disease (IBD, 15%), and axial spondyloarthritis (AxSpA, 11%), and the most prevalent cancers were lung cancer and melanoma. Anti-PD-1 therapies were given to all patients; two patients also received sequential anti-CTLA-4 therapy.

Over a median follow-up of 11 months (interquartile range, 6-17.5 months), about half of patients experienced disease exacerbations (52%); 14% were severe. Flares necessitated corticosteroids (57%), immunosuppression (50%), and ICI discontinuation (14%). A correlation was observed between a history of more intensive immunosuppression and increased risk for exacerbations.

Patients with psoriasis, IBD, and AxSpA were susceptible to rheumatic immune-related adverse events (IRAEs) such as polyarthritis and tenosynovitis.

A retrospective cohort study from 2019 observed similar findings. This study, which took place between January 2017 and January 2018 and consisted of three French national networks of oncology and autoimmunity experts, also included patients with PADs receiving ICIs.

A total of 112 patients were evaluated; median follow-up was 8 months. The most prevalent PADs in this study were psoriasis (n=31), RA (n=20), and IBD (n=14). At the time of ICI initiation, 24 patients were receiving immunosuppressive therapy. Overall, 53 patients exhibited a disease flare and 47 sustained other IRAE(s); these AEs necessitated immunosuppressive therapy (n=48) and permanent ICI discontinuation (n=24).

Patients who were receiving immunosuppressive therapy when ICI treatment was started had a shorter median progression-free survival (PFS, 3.8 months vs. 12 months, P=0.006). Median PFS was also shorter among patients who experienced flares or other IRAE(s).

Journal of Clinical and Cellular Immunology is pleased to inform you that the Journal is planning to launch its upcoming issue for the month of March 2021. We would like to invite you to submit your research work for publication in this international scholarly open-access journal. There are no space limitations or specific topics; journal publishes all manuscripts within the scope of the journal judged to be sound by editors.

Manuscripts submitted to the journal include, but are not limited to:

Journal accepts all kinds of manuscripts like Original Research Articles, Expert Review Articles, Case Reports, Mini Reviews, Brief Reports, Communications, Letter to Editor, Short Commentaries and Editorials.

Journal of Clinical & Cellular Immunology is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems used by most of the best open access journals. Review processing is performed by the editorial board members of Journal of Clinical & Cellular Immunology or outside experts; at least two independent reviewers approval followed by editor's approval is required for acceptance of any citable manuscript. An annual review of Immunology Journal is also shared with authors.

JCCI reviews manuscripts within 21 days of submission and publishes accepted manuscripts online in press immediately regardless of issue publication date. 

Authors are requested to submit manuscripts at https://www.longdom.org/submissions/clinical-cellular-immunology.html or send as an e-mail attachment to the Editorial Office at: immunology@eclinicalsci.com (or) immunology@scholarlymed.com

Media Contact:
Mercy Eleanor
Managing Editor
Journal of Clinical and Cellular Immunology
ISSN: 2155-9899 | NLM ID: 101563152
Journal Impact Factor 2.3* (5 Year Journal Impact Factor)
E-mail: immunology@eclinicalsci.com
What’s App: +1-504-608-2390